The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | Horizon scanning in interventional pulmonology: intratumoral therapy & tumor ablation
Christopher Manley, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses some of the exciting advances in interventional pulmonology on the horizon that could have a positive impact on lung cancer care. The direct injection of anti-tumor therapy into lung lesions could allow the use of lower therapeutic doses compared to current systemic therapies and could therefore reduce treatment-related side effects. Dr Manley also explains that tumor ablation could be a promising option for patients with lung cancer that are too fragile to undergo surgery or radiation and could offer a potential treatment for patients with metastatic disease. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
Disclosures
Dr Manley serves as a consultant for Johnson and Johnson and Auris Health. He has received research grant funding from Mauna Kea and Johnson and Johnson.
